Clinical Trials Browser

Recruiting × Pathologic Complete Response × regorafenib × Clear all

NCT04055220 2026-02-17

REGOSTA

Pathologic Complete Response, Bone Neoplasms, Chondrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Patient Compliance, Sarcoma, Ewing, Osteosarcoma, Histiocytoma, Malignant Fibrous